Increased UDP-glucuronosyltransferase activity and decreased prostate specific antigen production by biochanin A in prostate cancer cells

Cancer Research

Volumn 58, Issue 11, 1998, Pages 2379-2384

  Sun, Xiao Ya ^a   Plouzek, Cathie A ^a   Henry, James P ^a,b   Wang, Thomas T Y ^a   Phang, James M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Gillette Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BIOCHANIN A; FLAVONOID; GLUCURONOSYLTRANSFERASE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ARTICLE; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MALE; METABOLISM; PRIORITY JOURNAL; PROSTATE CANCER;

ANTICARCINOGENIC AGENTS; ENZYME ACTIVATION; FLAVONOIDS; GENISTEIN; GLUCURONOSYLTRANSFERASE; HUMANS; KINETICS; MALE; PEPTIDYLPROLYL ISOMERASE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE; TUMOR CELLS, CULTURED;

EID: 0032100644     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bélanger, A., Brochu, M., and Cliche, J. Levels of plasma steroid glucuronides in intact and castrated men with prostate cancer. J. Clin. Endocrinol. Metab., 62: 812-815, 1986.
2. Dutton, G. J. Glucuronidation of Drugs and Other Compounds. Boca Raton, FL: CRC Press, 1980.
3. Miners, J. O., and Mackenzie, P. I. Drug glucuronidation in humans. Pharmacol. Ther., 51: 347-369, 1991.
4. Henry, J. H., Welsh, C. J., and Phang, J. M. Differential metabolism of testosterone due to UDP-glucuronosyl transferase activity (UGT) in prostate cancer cells. Proc. Am. Assoc. Cancer. Res., 34: 248, 1993.
5. Guillemette, C., and Bélanger, A. Glucuronosyltransferase activity in human cancer cell line LNCaP. Mol. Cell. Endocrinol., 107: 131-139, 1995.
6. Tominaga, S. Cancer incidence in Japanese in Jypan, Hawaii, and Western United States. Natl. Cancer Inst. Monogr., 69: 83-92, 1985.
7. Barnes, S., Grubbs, C., Setchell, K. D. R., and Carlson, J. Soybeans inhibit mammary tumors in models of breast cancer. Prog. Clin. Biol. Res., 347: 239-253, 1990.
8. Catalona, W. J., Smith, D. C., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J., Petros, J. A., and Andriole, G. L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med., 324: 1156-1161, 1991.
9. Rittmaster, R. S., Leopold, C. A., and Thompson, D. L. Preferential metabolism of dihydrotestosterone to androstanediol 17-glucuronide in rat prostate. Endocrinology, 123: 2788-2792, 1988.
10. Lowry, O. R., Rosebrough, N. J., Farr, L., and Randall, R. J. Protein measurement with the Folin Phenol Reagent. J. Biol. Chem., 193: 267-275, 1951.
11. 18 cartridges. Clin. Chim. Acta, 122: 419-423, 1982.
12. Bélanger, A., Couture, J., Caron, S., and Roy, R. Determination of non-conjugated and conjugated steroid levels in plasma and prostate after separation on C-18 columns. In: L. Castagnetta, S. D'Aquino, F. Labrie, and H. L. Bradlow (eds.), Steroid Formation, Degradation, and Action in Peripheral Tissues, pp. 251-259. New York: New York Academy of Sciences, 1990.
13. Coffey, D. S. Physiological control of prostatic growth: a preview. In: D. S. Coffey and J. T. Isaacs (eds.), Prostate Cancer, pp. 4-23. Geneva: International Union Against Cancer, 1979.
14. Lehrach, H., Diamond, D., Wozney, J. M., and Boedtker, H. RNA molecular weight determinations by gel electrophoresis under denaturing conditions, a critical reexamination. Biochemistry, 16: 4743-4751, 1977.
15. Chen, F., Ritter, J. K., Wang, M. G., McBride, O. W., Lubet, R. A., and Owens, I. S. Characterization of a cloned human dihydrotestosterone/androstanediol UDP-glucuronosyltransferase and its comparison to other steroid isoforms. Biochemistry, 32: 10648-10657, 1993.
16. Burchell, B., Nebert, D. W., Nelson, D. R., Bock, K. W., Iyanagi, T., Jansen, L. M., Lancet, D., Mulder, G. J., Chowdhury, J. R., Tephly, T. R., Siest, G., and Mackenzie, P. I. The UDP glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence. DNA Cell Biol., 10: 487-494, 1991.
17. Ritter, J. K., Chen, F., Sheen, Y. Y., Tran, H. M., Kimura, S., Yeatman, M. T., and Owens, I. S. A novel complex locus UGTI encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J. Biol. Chem., 267: 3257-3261, 1992.
18. Hasel, K. M., and Sutcliffe, J. G. Nucleotide sequence of a cDNA coding for mouse cyclophilin. Nucleic Acids Res., 18: 4019, 1990.
19. Plouzek, C. A., Leslie, K. K., Stephens, J. K., and Chou, J. Y. Differential gene expression in the amnion, chorion, and trophoblast of the human placenta. Placenta, 14: 277-285, 1993.
20. Montgomery, B. T., Young, C. Y., Bilhartz, D. L., Andrews, P. E., Prescott, J. L., Thompson, N. F., and Tindall, D. J. Hormonal regulation of prostate-specific antigen (PSA) glucoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate, 21: 63-73, 1992.
21. Brochu, M., and Bélanger, A. Increase in plasma steroid glucuronide levels in men from infancy to adulthood. J. Clin. Endocrinol. Metab., 64: 1283-1287, 1987.
22. Brochu, M., and Bélanger, A. Comparative study of plasma steroid and steroid glucuronide levels in normal men and in men with benign prostatic hyperplasia. Prostate, 11: 33-40, 1987.
23. Rittmaster, R. S., Leopold, C. A., and Thompson, D. L. Androgen glucuronosyl transferase activity in rat liver, evidence for the importance of hepatic tissue in 5α-reduced androgen metabolism. J. Steroid Biochem., 33: 1207-1212, 1989.
24. Brochu, M., Bélanger, A., Dupont, A., Cusan, L., and Labrie, F. Effect of flutamide and aminoglutethimide on plasma 5α-reduced steroid glucuronide concentrations in castrated patients with cancer of the prostate. J. Steroid Biochem., 28: 619-622, 1987.
25. Hudson, R. W., Moffitt, P. M., and Owens, W. A. Studies of the nuclear 5α-reductase of human prostatic tissue: comparison of enzyme activities in hyperplastic, malignant, and normal tissues. Can. J. Biochem. Cell Biol., 61: 750-755, 1983.
26. Orlowski, J., and Clark, A. F. Epithelial-stromal interactions in the regulation of rat ventral prostate function: identification and characterization of pathways for androgen metabolism in isolated cell types. Endocrinology, 128: 872-884, 1991.
27. Halgunset, J., Sunde, A., and Lundmo, P. I. Retinoid acid (RA): an inhibitor of 5α-reductase in human prostatic cancer cells. J. Steroid Biochcm., 28: 731-736, 1987.
28. Chung, L. W., and Coffey, D. S. Androgen glucuronide II. Differences in its formation by human normal and benign hyperplastic prostates. Invest. Urol., 15: 385-388, 1978.
29. Bélanger, A., Brochu, M., Lacoste, D., Noël, C., Labrie, F., Dupont, A., Cusan, L., Caron, S., and Couture, J. Steroid glucuronides: human circulatory levels and formation by LNCaP cells. J. Steroid Biochem. Mol. Biol., 41: 593-598, 1991.
30. Guillemette, C., and Bélanger, A. Glucuronosyltransferase activity in human cancer cell line LNCaP. Mol. Cell. Endocrinol., 107: 131-139, 1995.
31. Bélanger, G., Beaulieu, M., Marcotte, B., Levesque, E., Guillemette, C., Hum, D. W., and Bélanger, A. Expression of transcripts encoding steroid UDP-glucuronosyltransferases in human prostate hyperplastic tissue and the LNCaP cell line. Mol. Cell. Endocrinol., 113: 165-173, 1995.
32. Harborne, J. B., and Grayer, R. J. Flavonoids and pollination biology. In: J. B. Harborne (ed.), The Flavonoids, pp. 589-617. London: Chapman and Hall Press, 1994.
33. Harborne, J. B. Nature, distribution and function of plant flavonoids. Prog. Clin. Biol. Res., 213: 15-24, 1986.
34. Stoner, E. 5α-Reductase inhibitors/finasteride. Prostate Suppl., 6: 82-87, 1996.
35. Nickel, J. C., Fradet, Y., Boake, R. C., Pommerville, P. J., Pereaulet, J. P., Afridi, S. K., and Elhilali, M. M. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar safety plus efficacy Canadian two year study. Can. Med. Assoc. J., 155: 1251-1259, 1996.